This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
This fall marks the beginning of an eight-year study that seeks to determine if those persons considered to be most susceptible to developing chronic bronchitis and emphysema can avoid these problems if they stop smoking and—when deemed necessary—use certain medications.
The National Heart, Lung, and Blood Institute, which is one of the National Institutes of Health located in the Washington, DC, suburb of Bethesda, Md, says the protocol development phase of the study began eight weeks ago. It is being conducted through ten North American centers, supported by grants from the institute's Division of Lung Diseases. The estimated total cost is expected to be about $2.5 billion, and at least 6,500 patients will be involved.
Each of the ten centers is called a Clinical Center for Early Intervention for Chronic Obstructive Pulmonary Disease. At the University of Alabama School of Medicine, Birmingham, which has been awarded a $2,506,769 grant for
Intervention trial begins with young smokers. JAMA. 1984;252(20):2802. doi:10.1001/jama.1984.03350200006002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: